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Abstract: The cellular and molecular basis of choline uptake on PET imaging and MRS-visible
choline-containing compounds is not well understood. Choline kinase alpha (ChoKα) is an enzyme
that phosphorylates choline, an essential step in membrane synthesis. We investigate choline
metabolism through 18F-fluoromethylcholine (18F-FMC) PET, MRS, and tissue ChoKα in human
glioma. Fourteen patients with a suspected diffuse glioma underwent multimodal 3T MRI and
dynamic 18F-FMC PET/CT prior to surgery. Co-registered PET and MRI data were used to target
biopsies to regions of high and low choline signal, and immunohistochemistry for ChoKα expression
was performed. The 18F-FMC/PET differentiated WHO (World Health Organization) grade IV from
grade II and III tumours, whereas MRS differentiated grade III/IV from grade II tumours. Tumoural
18F-FMC/PET uptake was higher than in normal-appearing white matter across all grades and
markedly elevated within regions of contrast enhancement. The 18F-FMC/PET correlated weakly
with MRS Cho ratios. ChoKα expression on IHC was negative or weak in all but one glioblastoma
sample, and did not correlate with tumour grade or imaging choline markers. MRS and 18F-FMC/PET
provide complimentary information on glioma choline metabolism. Tracer uptake is, however,
potentially confounded by blood–brain barrier permeability. ChoKα overexpression does not appear
to be a common feature in diffuse glioma.
Keywords: brain; choline; glioma; MRI; PET
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1. Introduction
Gliomas are the most common primary brain tumour in adults and one of the most frequent cause
of cancer related death in young adults aged 20–39 in countries with a very high human development
index [1]. Behaviour and prognosis of individual gliomas is highly variable and there is a need for
objective imaging biomarkers to permit reliable stratification for appropriate therapy. MRI is the
modality of choice for the diagnosis and follow-up of patients with a glioma. Advanced MR techniques
are becoming more widely used to characterize altered metabolism and other pathological features
in these tumours. Choline is a naturally existing substrate that is transported intracellularly and
phosphorylated in cells to phosphocholine by the enzyme choline kinase alpha (ChoKα), to eventually
yield phosphatidylcholine, an essential phospholipid for cell membrane production [2]. Deregulated
cell proliferation in malignant cells is associated with increased membrane turnover and higher
concentrations of membrane components manufactured via the Kennedy pathway [3]. Thus, choline
metabolism is recognized as a marker of tumour cell proliferation [4].
Magnetic resonance spectroscopy (MRS) can measure tumour metabolites non-invasively.
The Cho resonance at 3.2 ppm, comprises varying proportions of ‘choline-containing
compounds’ (predominantly phosphocholine, phosphoethanolamine, glycerophosphocholine,
and glycerophosphoethanolamine) involved in phospholipid synthesis and degradation [3]. Cho is
often expressed as a ratio to creatine/phosphocreatine (Cr, 3.0 ppm). Several studies in glioma have
shown a correlation between elevated MRS Cho levels and the cell proliferation marker Ki-67 [5,6],
as well as correlation of the Cho/Cr ratio with Ki-67 [7,8]. The choline signal on MRS is thought to be
useful in determining the grade of glioma [9] and the presence of anaplastic transformation [10].
Choline metabolism may be evaluated non-invasively in-vivo using radiotracers imaged with
PET. 18F-fluoromethylcholine (18F-FMC) has been shown to mimic closely endogenous choline uptake
in normal tissue and prostate cancer [11]. In glioma imaging, pilot clinical studies have shown
differential uptake of choline radiotracers between glioma and normal brain tissue, and between glioma
and other disease processes. For example, a pilot study in 12 patients by Hara et al. found higher
tumour-to-background tissue ratios using 18F-fluoroethylcholine compared with 11C-choline [12].
Subsequently, a larger study of 30 patients looking at 18F-FMC uptake in solitary brain lesions
showed differential uptake between benign lesions, high grade gliomas, and metastatic lesions [13].
The relationship between choline radiotracer uptake and MRS-visible metabolites has not previously
been studied in human glioma.
ChoKα is known to be overexpressed in lung, prostate, and colorectal carcinomas [14]. In ex-vivo
glioma cells, genomic analysis has linked phosphocholine measured on MRS to the expression of choline
kinase β (ChoKβ) and phospholipase genes [15]. However, in this small study, no increased expression
of ChoKα was identified. ChoKα is, however, considered to be essential for phosphatidylcholine
synthesis, and in vitro tumour cell line studies have shown overexpression of ChoKα and not
ChoKβ [16]. How ChoKα expression is related to imaging markers of choline metabolism in vivo in
glioma is unclear.
In this prospective study, we investigated the relationship between choline metabolites measured
with MRS, uptake of 18F-FMC with PET/CT imaging, and expression of ChoKα in spatially correlated
glioma tissue from targeted biopsies.
2. Method
2.1. Patients
Fourteen patients (7 male, 7 female; aged 23–73 years, mean 40 years) were recruited to this study.
Inclusion criteria were age >18 years, suspected primary supratentorial glial tumours, lesions greater
than 2 cm, WHO (World Health Organization) performance status ≤2, considered suitable for biopsy
and/or resection by the neuro-oncology MDT at Imperial College Healthcare NHS Trust. One patient
was diagnosed with a dysembryoplastic neuroepithelial tumour (DNT) and was excluded from further
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tissue analysis. Patients previously treated with radiotherapy, cytotoxic agents, or other experimental
drugs were excluded from the study. The study was reviewed and approved by the London—Fulham
Research Ethics Committee. Written and informed consent was obtained before recruitment to the study
and all data were anonymized in accordance with the General Data Protection Regulation (GDPR).
2.2. Image Acquisition
PET/CT (13/14 patients) and MRI (14/14 patients) were performed prior to surgery; both modalities
on the same day in 12/14 patients, and in one case 7 days apart.
MR images were acquired on a 3T Siemens Verio MRI system (Siemens, Erlangen, De; VB19)
using a 32-channel head coil. The MR protocol included pre- and post-gadolinium high resolution 3D
volumetric T1 images (voxel size 1 × 1 × 1 mm); MR spectroscopy (MRS) using a 2D chemical shift
imaging (CSI) sequence (PRESS: TE = 30 ms, TR = 1700 ms, voxel size 10 × 10 × 15 mm); and total
acquisition time for one CSI slice was 7 min. Between one and three CSI slices were acquired per
patient to cover the whole tumour where possible.
PET/CT was performed on a Siemens Biograph 6 scanner. Following patient positioning, a CT
scan (50 mAs, 110 kV, 0.6 pitch, 1.0 sec rotation, 6 × 2.0 mm collimation, 3 mm slices) was performed
for attenuation correction and co-registration. The 18F-FMC (PETNET Solutions Inc., Northwood, UK)
was injected as a bolus injection intravenously (mean activity 261 MBq, target maximum activity 285
MBq) and a dedicated 45-min brain dynamic list mode acquisition was performed. The administration
of radioactivity for the PET scans was approved by the Administration of Radioactive Substances
Advisory Committee, United Kingdom. In one patient, 154 MBq of 18F-FMC was injected, and in
another patient the acquisition was halted after 38 min as the patient needed to micturate.
Discrete venous blood samples of 5 mL were taken during scanning in 8 of the 14 patients. Samples
were taken at 2.5, 5, 7.5, 10, and 45 min post-injection in the first two patients and at 1, 2, 3, 4, 5, 10,
and 45 min post-injection in the next 6 patients. The start and end withdrawal times for the venous
sampling were recorded.
2.3. Tumour Biopsies
Thirteen of the 14 patients underwent surgical resection or biopsy at Charing Cross Hospital,
London UK, 1–51 days (mean 17 days) after imaging. One patient opted to undergo surgical resection
at a different institution, precluding ChoKα analysis, although neuropathological diagnosis was made
available for that patient. Regions of both high and low Cho/Cr ratios on MRS and 18F-FMC uptake on
PET were marked for biopsy by neurosurgeons using color-coded hollow virtual spheres represented
in the surgical neuronavigational system using methodology described previously [17]. Biopsies were
obtained in 1–4 regions per patient and the regions sampled were recorded on the neuronavigational
systems for correlation with imaging parameters. One to two samples from each patient were used for
ChoKα analysis.
2.4. Tissue Analyses
Samples were analysed at The University of Manchester and Imperial College London using both
automated and manual immunohistochemistry staining. Tumour specimens were evaluated by a
neuropathologist (F.R.) according to the integrated approach recommended by the revised 4th edition
of the WHO classification of brain tumours [18]. IHC for ChoKα was performed on 1–2 samples per
patient to cover a range of high to low Cho/Cr ratios on MRS and high to low 18F-FMC uptake on
PET. Serial 4 µm sections from formalin fixed, paraffin embedded tissue were cut on to Superfrost Plus
slides then heated at 60 ◦C for 45 min prior to staining.
IHC ChoKα detection was performed both by manual and automated methods using two
commercially available ChoKα antibodies as described below. An appropriate positive control
(bronchial biopsy) was included for each slide. A negative control was performed by the addition
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of diluent only during primary antibody incubation. IHC stained sections were reviewed by a
neuropathologist (F.R.).
Manual staining of clone HPA024153 (Sigma-Aldrich, St. Louis, MO, USA) was performed as
follows. Slides were dewaxed by immersion in Histo-Clear (National Diagnostics USA, Atlanta,
GA, USA) and rehydrated with subsequent immersion in 100% ethanol, 70% ethanol, and distilled
water. Antigen retrieval was performed by immersion in 95 ◦C TRIS-EDTA buffer (Sigma-Aldrich
Ltd.) comprised of 1M Tris-HCl (pH approximately 8.0) containing 0.1M EDTA for 30 min in a Grant
SUB Aqua 5 Plus water-bath. Slides were rinsed in PBS and endogenous peroxidase activity blocked
by immersion in 0.3% hydrogen peroxide (Sigma-Aldrich Ltd.) in PBS for 15 min. Thereafter, slides
were rinsed with PBS and incubated with 1.5% normal goat serum (Vector Laboratories, Burlingame,
CA, USA) for 30 min prior to incubation with primary antibody HPA024153 (Sigma-Aldrich, 1/80) at
room temperature for one hour. Slides were rinsed in PBS and incubated with secondary biotinylated
antibody (Goat Anti-Rabbit IgG, Vector Laboratories, 1/100) for 30 min followed by an avidin/biotin
peroxidase complex (VECTASTAIN Elite ABC Kit, Vector Laboratories) for 30 min. Chromogenic
reaction was developed using DAB (Diaminobenzidine, Vector ImmPACT DAB Peroxidase Substrate)
for 1 min then halted by immersion in running tap water for 5 min. Nuclei were counterstained with Gill 2
Haematoxylin (Thermo Fisher Scientific Shandon, Runcorn, UK) and blued in Scott’s tap water (in-house
preparation) for 1 min. Slides were dehydrated in 70% ethanol and 100% ethanol, cleared in Histo-Clear
(National Diagnostics USA, Atlanta, GA, USA), and mounted in DPX (VWR BDH ProLab, Wirral, UK).
Automated staining of clone NBP1-85630 (Novus Biologicals, Littleton, CO, USA) was performed
using a Ventana Roche Benchmark Ultra autostainer (Hoffmann-La Roche LTD, Atlanta, CA, USA).
Slides were subjected to 76 min heat-induced epitope retrieval using Ventana Ultra CC1 (EDTA based
pH 9.0) prior to primary antibody incubation at 1/100 for 60 min. Detection and subsequent nuclear
counterstaining were performed with Ventana Ultraview Detection Kit and Ventana Haematoxylin.
Slides were dehydrated in gradated ethanol, cleared in xylene, and mounted in DPX (VWR BDH
ProLab, Wirral, UK).
2.5. Data Analyses
2.5.1. Venous Sampling
Start and end withdrawal times were recorded for each sample taken from the venous cannula,
and the mean withdrawal time calculated. Well-counting of blood samples was carried out for
each time-point to quantify the level of radioactivity in each sample, followed by well-counting of
plasma obtained from spun-down blood samples. Venous blood samples were processed before
high-performance liquid chromatography (HPLC) analysis. Proteins were removed using Acetonitrile
precipitation of cell free plasma, followed by vacuum rotary evaporation. The dried-down sample
was reconstituted with mobile phase followed by Millipore filtration. The filtered solution was then
injected onto a 1 mL sample loop, in readiness for HPLC analysis. The resultant solution was analysed
with sensitive radioactivity detection, by HPLC (Phenonenex Luna 10 µ SCX 100 A, 250 × 4.6 mm i.d.)
at a flow rate of 2 mL/min. The mobile phase used for elution was sodium di-hydrogen orthophosphate
(0.25 M) and acetonitrile (90:10). The radioactive detector was linked to a PC based integrator, Agilent
software, and the 18F-Choline content obtained from integrated radioactivity traces. The fraction of
parent compound was measured and plotted against the mean withdrawal time.
2.5.2. Dynamic Image Analysis
Raw PET data were attenuation and scatter corrected, then reconstructed iteratively (dynamic
data: 2 iterations, 8 subsets; static data: 8 iterations, 16 subsets). Processed PET data were analysed
using a dedicated PET workstation (Hermes Medical Solutions, Stockholm, Sweden). The dynamic PET
images were reviewed alongside MR images by two experienced observers (T.B., A.W.) in consensus to
manually outline volumes of interest (VOI) for quantitative standardised uptake value (SUV) analysis
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and to generate time activity curves. Dynamic data was available in 12/13 patients who had a PET
scan. One of the patients was excluded from the dynamic data analysis due to motion artefact. In these
12 patients, time activity curves of SUVmax against time were drawn for each of the tumours according
to WHO grade and for a 2 cm spherical region of interest (ROI) in contralateral white matter.
2.5.3. Static Image Analysis
Considering the time activity curves and results from the venous sampling, the most stable time
period of 7–17 min was chosen as the optimum time window for reconstruction and analysis of static
18F-FMC PET images in all 13 patients who underwent PET. These images were used for analysis of
SUVmax and measurements of the tumour-to-background ratio (TBR). TBR was calculated considering
the tumour SUVmax and SUVmean in a 2 cm diameter spherical ROI in the contralateral white matter
(WM) as shown in Equation 1 and presented in [13,19].
TBR =
[SUVmax]tumour
[SUVmean]WM
(1)
2.5.4. MR Spectroscopy
MRS data were analysed using TARQUIN [20] to extract values for total choline containing
compounds (Cho) and total creatine containing compounds (Cr). Data were eddy current corrected and
the ratio of Cho/Cr was extracted for all relevant voxels. The TARQUIN Cho/Cr ratio was converted
from relative metabolite concentration to peak intensity by multiplying it by 9/3 for comparison with
literature values. [Cho/Cr]max was measured as the maximum Cho/Cr ratio within the tumour regions
across all slices over which the spectroscopy data were acquired. Relative values were used to select
high and low Cho/Cr regions within individual tumours. A pragmatic Cho/Cr threshold of 2.4 was
used to define regions of high and low Cho/Cr for the purposes of comparison with ChoKα staining.
2.5.5. Imaging vs. Tumour Grade
SUVmax, TBR, and [Cho/Cr]max ratios on MRS were used to interrogate the ability of these imaging
parameters to differentiate between the various tumour grades. The Shapiro–Wilk test was used to test
for normality. As the distributions were found to be not normal, the Wilcoxon rank-sum test was used
to test the difference in means between the various tumour grades. Data were tested over 12 patients
for PET and 13 patients for MRS: Patient 13 (P013) was excluded from analyses as they were diagnosed
as a diffuse neuroepithelial tumour (DNET), and for patient 6 (P006), PET data were not acquired.
2.5.6. Correlating 18F-FMC PET Uptake and Cho/Cr Ratio
The Cho/Cr ratio on MRS and the TBR on 18F-FMC PET were correlated to analyse the relationship
between the two imaging parameters, both in terms of spatial location as well as the numerical
measure. MRS location was extracted and compared to the PET images as previously described [17].
PET static images were registered to the post-contrast T1 weighted image over which the MRS voxel
locations were extracted using a normalized mutual information method and trilinear interpolation
in FLIRT (FSL). The co-registered PET image, post-contrast T1 weighted image, and the MRS voxel
locations were overlaid in order to compare the spatial location differences for [Cho/Cr]max and TBR.
The quantitative values were then correlated by extracting the SUV values in each region of viable
MRS data. The sample to background ratio (SBR) was measured as the mean SUV in the MRS ROI
divided by the mean SUV in the contralateral white matter. The SBR was plotted against the Cho/Cr
ratio, grouping patients into the different tumour grades. The correlation between the two was tested
using the Pearson correlation coefficient in MATLAB.
SBRROI =
[SUVmean]ROI
[SUVmean]WM
(2)
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2.5.7. Choline Uptake and Contrast Enhancement on MRI
Regions of very high 18F-FMC uptake were also correlated with regions of contrast enhancement
by overlaying the two and measuring the percentage overlap between contrast enhancement and high
18F-FMC uptake. ROIs were drawn on contrast enhancing regions for each of the enhancing tumours.
Regions with the highest 18F-FMC uptake within the tumour were defined as at least three times the
SUVmean of the contralateral white matter. The percentage of contrast enhancing voxels with high
18F-FMC uptake was then calculated by dividing the number of voxels with high 18F-FMC uptake
within the contrast enhancing region over the number of voxels within the contrast enhancing region.
Non contrast enhancing regions of tumours that were hyperintense on T2 FLAIR were also defined, and
the percentage of voxels with an uptake higher than the threshold was also calculated for comparison.
2.5.8. Correlation between Imaging and Tissue Parameters
Spherical ROIs (8 mm diameter) were drawn using MRIcron in each of the biopsied regions using
recordings obtained from the neuronavigational software. In addition, a 2 cm diameter spherical ROI
was drawn around contralateral white matter for each patient to measure the sample-to-background
ratio (SBRbiopsy) for each biopsied sample. The ROIs were drawn on the post-contrast T1 weighted
image, to which the static PET images were registered. A selection of 1 to 2 samples per patient were
chosen to cover a range of SBRbiopsy and [Cho/Cr]biopsy ratios for further tissue analyses.
3. Results
3.1. Neuropathology
A summary of patient tissue data, including molecular diagnosis, is shown in Table 1. Of the
14 patients, 3 were diagnosed as WHO grade IV tumours, 4 as WHO grade III tumours, 6 as WHO
grade II tumours, and 1 as a WHO grade I tumour. The patient diagnosed with a dysembryoplastic
neuroepithelial tumour was excluded from comparative analyses.
Table 1. Summary of patient tissue data and corresponding PET and MRS results from each sample. M
= mutant, WT = wild type, R = retained, CD = codeleted, U = unknown, ChoKα = negative, DNET
= diffuse neuroepithelial tumour. Patient 6 (P006) did not have a PET scan, and the location of the
surgical resection was not recorded, excluding them from tissue vs. imaging analyses. P007 did not
undergo surgical resection at our institution and hence no tissue data were available. P013 (DNET) was
excluded from the analyses. Grey cells: data unavailable.
Subject Tumour Type,
WHO Grade
Molecular Sample 1 Sample 2
IDH1 1p/19q ATRX SBR(PET)
Cho/Cr
(MRS) ChoKα
SBR
(PET)
Cho/Cr
(MRS) ChoKα
P001 Astrocytoma, II M R M 1.6 1.05 - 1 1.86 -
P002 Oligodendroglioma, III M U WT 3.4 1.8 - 2.2 0.42 -
P003 Oligodendroglioma, III M CD WT 4.4 1.65 - 3.6 1.68 weak
P004 Astrocytoma, III WT R M 0.8 0.9 - 0.8 1.59 -
P005 Oligodendroglioma, II M R M 1 0.96 - 1.1 1.23 weak
P006 Oligodendroglioma, II M U WT unrecordedlocation weak
unrecorded
location weak
P007 Astrocytoma, II surgery at external institution
P008 GBM M R M 5.6 1.02 weak no second sample
P009 GBM WT R M 9.3 N/A weak 7.3 1.77 weak
P010 GBM WT R U 43 2.88 strong 20 2.7 -
P011 Astrocytoma, III M R M 3.1 1.89 - 3.9 2.91 weak
P012 Astrocytoma, II M R M 1.3 1.53 - 1.2 0.75 weak
P013 DNET, I excluded from analyses
P014 Astrocytoma, II M R M 2.7 0.84 - no second sample
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3.2. Metabolite Analysis
Results for the metabolite analysis carried out through venous sampling in 8 patients are shown
in Figure 1A. Fifty percent of the 18F-FMC was metabolized between 7.5 min (WHO grade II tumour)
and 42.5 min (WHO grade III tumour) post-injection. The main metabolite was betaine. A second and
third metabolite peak were observed in three patients at a single time-point. Following results from
the first two patients, which showed rapid metabolism of the parent compound, venous sampling was
changed from every 2.5 min in the first 10 min to every minute in the first five minutes.
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Figure 1. (A) Metabolite analysis. The graph shows a plot of the parent fraction against the mean
withdrawal time for venous sampling from 8 patients. The time taken to metabolize 50% of 18F-FMC
was 7.5–42.5 min. (B) Time activity curves by tumour grade. The plot of maximum standardised uptake
value (SUVmax) against time is shown for each of the tumour grades grouped together and the average
contralateral white matter. Uptake was higher in all tumours compared to contralateral white matter
with the highest uptake in the WHO grade IV tumours. Uptake of 18F-FMC was rapid within the first
5 min before reaching a steady-state.
3.3. Time Activity Curves
Time activity curves (Figure 1B) show rapid uptake within the first five minutes and increased
uptake in all tumours compared to contralateral white matter. Considering the time activity curves
and metabolite analysis for each of the individual patients, the 7–17 min time period was identified as
the most stable for static image analysis.
3.4. TBR and SUVmax vs. Tumour Grade
Using both TBR and SUVmax we were able to differentiate between WHO grade IV tumours and
the rest of the tumours combined (p < 0.01). A box plot for SUVmax by tumour grade is shown in
Figure 2A. The highest uptake was observed in WHO grade IV tumours. All tumours had a hi her
uptake t an that of the respective normal-appearing contralateral white matter.
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Figure 2. (A) SUVmax by tumour grade. Box plots for SUVmax are shown by tumour grade and in
normal appearing contralateral white matter (NAWM). Wilcoxon rank-sum test showed a significant
difference between HO grade IV tumours and all other tumours. SUV ax was unable to differentiate
between the other tumours. (B) Maximum Cho/Cr ratio by tumour grade. Box plots for [Cho/Cr]max by
tumour grade show a statistically significant difference between WHO grade III and WHO grade II
tumours but not between grade IV tumours and the other tumours.
3.5. MR Spectroscopy vs. Tumour Grade
Results for comparing maximum choline to creatine ratios according to tumour grade are shown
in the boxplot in Figure 2B. Using [Cho/Cr]max we were able to differentiate between WHO grade
II and WHO grade III tumours (p < 0.01). Grouping WHO grade III and WHO grade IV tumours
as high-grade tumours, and WHO grade II tumours as low-grade tumours, showed a statistically
significant difference between the two groups (p < 0.01).
3.6. FMC-PET Uptake vs. MR Spectroscopy
Of the 14 patients, 1 did not have good quality spectra, 1 did not have PET images, and 3 did not
have significantly elevated 18F-FMC uptake. In the remaining 9 patients, regions of highest 18F-FMC
uptake correlated spatially with regions of highest Cho/Cr ratio in the regions where good quality MRS
data were available.
The correlation between 18F-FMC-uptake and Cho/Cr ratio was tested in 12/14 patients and
257 MRS voxels were used. Correlating the two measures showed a significant moderate-positive
correlation between 18F-FMC uptake and Cho/Cr ratio (r = 0.59, p << 0.001). When considering WHO
grade IV tumours alone, a strong positive correlation between the two measures (r = 0.9, p << 0.001)
was demonstrated. It was noted that all of the data points shown in Figure 3 with an SBR over
10 resulted from a single patient. Excluding that patient from the analysis showed a weak positive
correlation between SBR and Cho/Cr ratio (r = 0.24, p << 0.001).
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Figure 3. 18F-FMC uptake vs. Cho/Cr ratio. A plot of mean sample-to-background (SBRmean) against
Cho/Cr ratio showed a moderate significant positive correlation between the two measures (r = 0.59,
p < 0.001), and a strong significant positive correlation when considering WHO grade IV tumours
alone (r = 0.9, p < 0.001). All data points with an SBR over 10 were from a single patient. Excluding
that patient resulted in a weak significant positive correlation between 18F-FMC-uptake and Cho/Cr
(r = 0.24, p < 0.001).
3.7. ChoKα Expression
Optimization for ChoKα staining in testes is shown in Figure 4A,D; results are similar to those
shown on Protei Atlas [21]. Tissue sample details are shown in Table 1. Of the 22 a ples analysed,
only one sh wed strong ChoKα staining. Samples wit high PET uptake (d fined as r gio s with an
SBR gr ater than 2.0) and igh Cho/Cr on MRS (defined as a Cho/Cr gr ater than 2.4) did not correlate
with tissue expressio of C oKα. Figure 4 shows sample images from regions with b th high and
low PET uptake, exhibiting both positive and negative ChoKα. Similar r sults were o tained for MRS.
Of note, staining for ChoKα was only strong in one of the 22 samples (compare Figure 4A–C). This
sample was from a patient ith GBM with the highest choline uptake on PET and second highest
Cho/Cr on MRS (Figure 4B). However, a second sample from this patient in a region of high choline
uptake and Cho/Cr was negative for ChoKα.
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Figure 4. Choline kinase alpha staining. Positive (A, ×10) and negative (D, ×10) control staining
for ChoKα in testes are shown. Glioma tumour tissue samples exhibiting regions of high PET
sample-to-background ratio (SBR) (B: SBR = 42.6; E: SBR = 3.1) showed both positive and negative
ChoKα staining. Glioma tumour tissue samples exhibiting regions of low SBR (C: SBR = 1.09; F: SBR
= 1.6) showed both positive and negative ChoKα staining. Samples shown are from four different
patients: GBM (B, 20×), WHO grade II Astrocytoma (C, 20×), WHO grade III Anaplastic Astrocytoma
(E, 20×), WHO grade II Astrocytoma (F, 20×). MRS Cho/Cr was high for sample B (2.88), and low for
samples C (1.23), E (1.89), and F (1.05).
3.8. Choline PET Uptake vs. Contrast Enhanced T1 MRI
Seven of the patients showed regions of contrast enhancement (3 WHO grade IV, 2 WHO grade III,
1 WHO grade II, 1 WHO grade I). Overlaying areas of highest 18F-FMC uptake on contrast-enhanced
T1 weighted imaging (Figure 5) showed that on average 94% of the volume of contrast enhancement
had an uptake above the threshold, which was defined as three times the uptake in contralateral white
matter. Of the 7 patients showing regions of contrast enhancement, 5 showed high 18F-FMC uptake in
100% of the contrast enhancing regions, 1 in 92% (WHO grade IV), and 1 in 67% (WHO grade III). In
comparison, when analysing hyperintense regions on T2 FLAIR and excluding regions of contrast
enhancement in these 7 patients, an average of 39% (min 1%, max 89%) of the volume of non contrast
enhancing tumour showed 18F-FMC uptake greater than the threshold. Of note, the grade I DNET,
whic was excluded from formal comparative analysis, showed contrast enhancement and markedly
elevated 18F-FMC uptake.
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Figure 5. The 18F-FMC uptake (right, red) a c trast enhancement on MRI (left) in two patients
with GBM. Overlaying 18 -FMC PET onto trast T1 weighted MRI showed that areas of
contrast enhancement had a high 18F-FMC-uptake (white arrows). Overall, an average 94% of contrast
enhancing regions had a 18F-FMC-uptake above the threshold, which was defined as three times that
in the contralateral white matter. Note the normal high uptake in the choroid plexus and bone marrow.
4. Discussion
4.1. 18F-FMC Metabolism
The 18F-FMC PET was metabolized rapidly. Between 46% and 72% of the 18F-FMC was
metabolized at 10 min post injection. When considering late PET image analyses, the majority of the
radiotracer would have been metabolized to betaine, making it difficult to discriminate between the
contributions of the parent compound and the catabolite [22]. The time activity curves showed rapid
uptake of choline in the tumours within the first five minutes and relatively stable activity thereafter,
in keeping with the findings of Mertens et al. [19]. Based on the TAC and metabolite analysis, 7–17 min
was chosen as the most stable time point for static image analyses of PET data.
4.2. 18F-FMC Uptake and Cho/Cr in Glioma Grading
The 18F-FMC PET and MRS appear to give compli entary information with regard to glioma
grade. The 18F-FMC PET uptake differentiated glioblastomas (WHO IV) from grade II/III, whereas
Cho/Cr distinguishe between grade II nd grade III/IV lesions, which is diagnostically important in
terms of current treatment regimens. Numerous previous studies have shown the potential of MRS,
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which has limited spatial resolution, to distinguish between low and high grade tumours [9,10]. In our
study, high 18F-FMC uptake appears to identify GBM. An earlier study of 11C-choline and 18F-FMC
in 12 suspected glioma cases also showed higher choline uptake in higher grade tumours, but their
study comprised predominantly WHO Grade IV cases [12]. The degree to which uptake in GBM is
confounded by the blood–brain barrier breakdown in these enhancing tumours is unclear.
Molecular subtypes, particularly IDH and 1p/19q, as well as grade are important determinants of
glioma phenotype and behaviour as emphasized in the WHO 2016 guidelines, and further work is
required in a larger cohort of patients to explore relationships between these and imaging markers
of choline metabolism. Importantly, both 18F-FMC PET and MRS offer spatial information which
can be used to distinguish regions that are more aggressive to guide targeted representative biopsies.
This is well-illustrated in one patient with anaplastic oligodendroglioma, where regions of high choline
uptake on PET correlated with the histologically higher-grade component of the tumour.
4.3. 18F-FMC PET Uptake and Contrast Enhancement
High 18F-FMC uptake was observed in 94% of contrast enhancing regions in seven patients.
Although this may reflect high localized metabolic activity, 18F-FMC uptake may be related to
blood–brain barrier deficiency. Structures that lack a blood-brain barrier (e.g., choroid plexus) have
been shown to display higher choline uptake than other regions of the brain [19]. Furthermore, a more
recent review indicated that choline radiotracers are affected by blood–brain barrier damage [23].
Our finding of high uptake in a DNET, a tumour type known to have low metabolic activity and
negligible malignant potential but in this case avid contrast enhancement, supports the view that
this may be a dominant mechanism. Modestly elevated choline uptake relative to normal-appearing
contralateral white matter in non-enhancing tumours does, however, suggest that some uptake is
genuinely due to choline metabolism. Further kinetic studies to examine the effects of blood–brain
barrier permeability on 18F-FMC uptake are needed to better understand 18F-FMC as a probe of
glioma choline metabolism and its clinical utility.
4.4. 18F-FMC PET vs. MRS
We found a moderate and significant positive correlation between SBR and the respective Cho/Cr
ratio over the whole tumour across all patients. Although there is a relationship between these two
parameters, there are clear differences in the way the modalities differentiate between tumour grade.
The processes probed by the two modalities differ: MRS Cho signal depends on steady-state levels of
intracellular compounds involved in both membrane synthesis and breakdown, whereas 18F-FMC PET
detects carrier-mediated flux of choline as a substrate for membrane synthetic pathways. Moreover,
the latter may also be confounded by non-specific uptake related to blood–brain barrier disruption,
as discussed above. Further studies are required to confirm the dominant processes influencing these
choline-related signals, and how they relate to key pathological processes in glioma.
4.5. Choline Kinase Alpha Expression
The largely negative results for ChoKα staining in the tissue samples were unexpected, and explain
the absence of significant correlation with imaging markers of choline metabolism, tumour grade,
and phenotype. We have not identified the significant levels of ChoKα expression seen in isolated
cell lines and correlated with 11C-choline uptake in vivo in other tumour types. In our cohort, it is
unlikely that the weak ChoKα staining observed in all but one of the positive samples was sufficient to
explain the 18F-FMC uptake on PET and elevated Cho/Cr on MRS. The degree to which xenografts
and syngeneic pre-clinical models recapitulate the metabolic environment in human diffuse gliomas,
especially those with IDH and p53 or 1p/19q mutations in unclear. High levels of staining were present
in only one sample from an IDH wild type GBM, however, another sample from the same tumour and
other wild type (WT) gliomas showed negative staining. We targeted ChoKα expression as the most
promising candidate tissue marker; it is possible that the ChoKβ isoform or other synthetic pathways
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may be of more relevance in gliomas. Phospholipid synthesis pathways, and in particular ChoKα, have
been proposed as potential therapeutic targets, and our negative results may be important in informing
such treatment strategies. In addition, the contribution of non-tumour cells such as infiltrating immune
cells could be addressed in future studies by labelling for microglia/macrophages.
4.6. Limitations
The study was limited by the small number of patients. In particular, there were only three
patients with GBM, and only three IDH wild type gliomas, although multiple samples were taken from
each lesion. Limitations for the correlation between imaging and tissue biomarkers include the limited
spatial resolution of the imaging techniques, relative imaging parameters applied for selecting biopsy
location, and accuracy of the neuronavigational system; we used a region with an 8 mm diameter,
allowing for an error margin that could be related to the system used or brain shift as discussed in [17].
Given the low ChoKα expression in this series, this is unlikely to have significantly biased our results.
The rapid metabolism of 18F-FMC to betaine also results in signals from a mixture of chemical species
in the later phases of PET acquisition. For practical reasons we have limited tissue analysis to ChoKα,
although, as discussed above, other enzymatic markers bear further exploration in this tumour type.
5. Conclusions
Correlation with relevant tissue features is important for better understanding and validating
of imaging biomarkers in spatially heterogenous diseases. ChoKα expression in diffuse glioma,
however, appears generally low, which limits the mechanistic conclusions that can be drawn in this
instance. The 18F-FMC PET and MRS provide complimentary information on glioma grade, and can
facilitate targeted biopsies from the most aggressive regions in order to guide individual patient
management. Improved understanding of factors affecting choline tracer uptake are needed for
widespread clinical implementation.
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